Table of Contents
ISRN Hepatology
Volume 2013 (2013), Article ID 412317, 9 pages
Clinical Study

Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients

1Biochemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza 11787, Egypt
2Biology Department, Faculty of Dentistry, October University for Modern Sciences and Arts (MSA), Giza 11787, Egypt
3Biochemsitry Department, National Hepatology and Tropical Medicine Research Institute, Fom El-Khalig, Cairo 11796, Egypt
4Faculty of Medicine, Ain Shams University, Cairo, Egypt

Received 30 June 2013; Accepted 12 August 2013

Academic Editors: D. Capone, A. Castiella, J. Inoue, B. Radosevic-Stasic, and Y. Yano

Copyright © 2013 Mohamed S. Othman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Interleukin-10 (IL-10) and interleukin-6 (IL-6) have been reported to be related to hepatocellular carcinoma (HCC) prognosis. This study aimed to investigate the clinical usefulness of serum levels of IL-6 and IL-10 as biomarkers for HCC among high-risk patients. Materials and Methods. 80 individuals were enrolled in this study; they were categorized into 4 groups: group 1 healthy individuals (NC) ( ), group 2 chronic hepatitis C virus (HCV) patients ( ), group 3 cirrhotic patients (LC) ( ), and HCC group ( ). Using ELISA technique serum levels of IL-6, IL-10, and alpha fetoprotein (AFP) were evaluated in all groups. Results. The mean serum levels of IL-6 were significantly higher in HCC than in LC, HCV, and NC groups ( , , , and ), respectively ( ); also the serum levels of IL-10 were significantly higher in HCC compared with LC, HCV, and NC groups ( , , , and ) ( ). We also found that the tumor size is correlated strongly with IL-6 and IL-10 levels ( , ; , ), respectively. Conclusion. The combination of those markers may help to identify a group of HCC patients with low AFP.